These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 29276288)
1. Hazardous Drug Contamination of Drug Preparation Devices and Staff: A Contamination Study Simulating the Use of Chemotherapy Drugs in a Clinical Setting. Call E; Bill B; McLean C; Call N; Bernkopf A; Oberg C Hosp Pharm; 2017 Sep; 52(8):551-558. PubMed ID: 29276288 [No Abstract] [Full Text] [Related]
2. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system. Brechtelsbauer E Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411 [TBL] [Abstract][Full Text] [Related]
3. Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process. Power LA; Sessink PJ; Gesy K; Charbonneau F Hosp Pharm; 2014 Apr; 49(4):355-62. PubMed ID: 24958942 [TBL] [Abstract][Full Text] [Related]
4. Challenges of Using Closed System Transfer Devices With Biological Drug Products: An Industry Perspective. Sreedhara A; Zamiri C; Goswami S; Weiser S; Cram M; Christian TR; Jagannathan B J Pharm Sci; 2020 Jan; 109(1):22-29. PubMed ID: 31697946 [TBL] [Abstract][Full Text] [Related]
5. Nurses' use of hazardous drug-handling precautions and awareness of national safety guidelines. Polovich M; Martin S Oncol Nurs Forum; 2011 Nov; 38(6):718-26. PubMed ID: 22037334 [TBL] [Abstract][Full Text] [Related]
6. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device. Siderov J; Kirsa S; McLauchlan R J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949 [TBL] [Abstract][Full Text] [Related]
7. An assessment of exposed syringe inner walls as a route of exposure from hazardous drugs. Barta BT; Armistead LT; Eckel SF J Oncol Pharm Pract; 2024 Feb; ():10781552241231511. PubMed ID: 38378187 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs). Besheer A; Mahler HC; Matter-Schwald A; Barrenechea SM; Vogt M; Chalus P; Heymes P; Pillow T; Kirste A; Favrod P; Joerg S; Mathaes R Pharm Res; 2020 Apr; 37(4):81. PubMed ID: 32274594 [TBL] [Abstract][Full Text] [Related]
9. Review of studies examining microbial contamination of vials used for preparations done with closed-system drug transfer devices. Soubieux A; Tanguay C; Bussières JF Eur J Hosp Pharm; 2021 Mar; 28(2):65-70. PubMed ID: 33608432 [TBL] [Abstract][Full Text] [Related]
10. Closed System Transfer Devices (CSTDs): Understanding Potential Over- and Under- Dosing of Liquid Vial Drug Products and How to Generally Mitigate. Lehermayr C; Schmelzer B; Kropf M J Pharm Sci; 2023 Sep; 112(9):2532-2537. PubMed ID: 37146755 [TBL] [Abstract][Full Text] [Related]
11. Assessment of unintended volume loss of six closed system transfer devices. Kulju S; McIntosh BA; Fuller HJ; Arnold T; Gunnar W J Oncol Pharm Pract; 2020 Jul; 26(5):1134-1140. PubMed ID: 31775580 [TBL] [Abstract][Full Text] [Related]
12. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. Gabay M; Johnson P; Fanikos J; Amerine L; Kienle P; Olsen M; Roussel C; Moody ML Am J Health Syst Pharm; 2021 Aug; 78(17):1568-1575. PubMed ID: 33773495 [TBL] [Abstract][Full Text] [Related]
13. Validation of chemotherapy drug vapor containment of an air cleaning closed-system drug transfer device. Levin G; Sessink PJ J Oncol Pharm Pract; 2022 Oct; 28(7):1508-1515. PubMed ID: 34229499 [TBL] [Abstract][Full Text] [Related]
14. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device. Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of a closed-system cytotoxic transfer device in a pharmaceutical isolator. Vyas N; Turner A; Clark JM; Sewell GJ J Oncol Pharm Pract; 2016 Feb; 22(1):10-9. PubMed ID: 25073678 [TBL] [Abstract][Full Text] [Related]
16. Development of a simple compatibility inspection method using pressure in a BD PhaSeal™ system and hazardous drug vials. Ishimaru H; Tsuda Y; Kage H; Kawano T; Takayama S; Morimoto Y; Goto K; Watanabe K J Oncol Pharm Pract; 2021 Sep; 27(6):1321-1327. PubMed ID: 32854576 [TBL] [Abstract][Full Text] [Related]
17. Closed safety system for administration (CSSA): proposal for a new cytotoxic chemotherapy acronym. Eisenberg S Br J Nurs; 2022 May; 31(10):S26-S32. PubMed ID: 35648666 [TBL] [Abstract][Full Text] [Related]
18. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies. Salch SA; Zamboni WC; Zamboni BA; Eckel SF Am J Health Syst Pharm; 2019 Apr; 76(9):591-598. PubMed ID: 31361828 [TBL] [Abstract][Full Text] [Related]
19. Performance testing protocol for closed-system transfer devices used during pharmacy compounding and administration of hazardous drugs. Wilkinson AS; Allwood MC; Morris CP; Wallace A; Finnis R; Kaminska E; Stonkute D; Szramowska M; Miller J; Pengelly I; Hemingway M PLoS One; 2018; 13(10):e0205263. PubMed ID: 30379831 [TBL] [Abstract][Full Text] [Related]
20. Occupational exposure to anti-cancer drugs: A review of effects of new technology. Vyas N; Yiannakis D; Turner A; Sewell GJ J Oncol Pharm Pract; 2014 Aug; 20(4):278-87. PubMed ID: 23975555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]